Edward Janoff
Concepts (587)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus pneumoniae | 40 | 2026 | 187 | 5.460 |
Why?
| | HIV-1 | 39 | 2024 | 913 | 4.280 |
Why?
| | Pneumococcal Infections | 21 | 2024 | 104 | 4.190 |
Why?
| | HIV Infections | 50 | 2025 | 3215 | 3.370 |
Why?
| | Immunoglobulin G | 37 | 2026 | 901 | 3.100 |
Why?
| | Antibodies, Bacterial | 26 | 2024 | 147 | 2.910 |
Why?
| | Meningitis, Cryptococcal | 10 | 2025 | 34 | 2.860 |
Why?
| | Pneumococcal Vaccines | 23 | 2021 | 130 | 2.680 |
Why?
| | Immunoglobulin A | 23 | 2022 | 205 | 2.560 |
Why?
| | AIDS-Related Opportunistic Infections | 15 | 2021 | 130 | 1.970 |
Why?
| | Bacterial Vaccines | 16 | 2000 | 63 | 1.720 |
Why?
| | B-Lymphocytes | 10 | 2024 | 887 | 1.450 |
Why?
| | Acquired Immunodeficiency Syndrome | 19 | 2014 | 238 | 1.400 |
Why?
| | Milk, Human | 9 | 2015 | 176 | 1.370 |
Why?
| | Cerebrospinal Fluid | 4 | 2025 | 88 | 1.300 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 5 | 2016 | 19 | 1.130 |
Why?
| | Vaccines, Conjugate | 8 | 2021 | 60 | 1.080 |
Why?
| | Pneumonia, Pneumococcal | 9 | 2026 | 48 | 1.050 |
Why?
| | Lymphocyte Activation | 8 | 2021 | 1137 | 1.020 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2026 | 69 | 0.920 |
Why?
| | Infectious Disease Transmission, Vertical | 5 | 2015 | 188 | 0.920 |
Why?
| | Serine Endopeptidases | 6 | 2022 | 129 | 0.910 |
Why?
| | Intestinal Mucosa | 7 | 2015 | 666 | 0.900 |
Why?
| | Viremia | 2 | 2018 | 158 | 0.880 |
Why?
| | Bronchiectasis | 1 | 2026 | 115 | 0.860 |
Why?
| | Microbiota | 3 | 2024 | 725 | 0.860 |
Why?
| | Immunoglobulin Variable Region | 4 | 2014 | 78 | 0.850 |
Why?
| | Nasopharynx | 2 | 2024 | 72 | 0.850 |
Why?
| | Antifungal Agents | 6 | 2025 | 153 | 0.820 |
Why?
| | Polysaccharides, Bacterial | 6 | 2007 | 70 | 0.820 |
Why?
| | Bacterial Capsules | 7 | 2014 | 33 | 0.790 |
Why?
| | Vaccination | 11 | 2021 | 1449 | 0.770 |
Why?
| | Adaptive Immunity | 4 | 2021 | 173 | 0.750 |
Why?
| | Antibodies, Viral | 3 | 2025 | 689 | 0.740 |
Why?
| | Diarrhea | 12 | 1997 | 190 | 0.720 |
Why?
| | Streptolysins | 6 | 1998 | 11 | 0.710 |
Why?
| | Plasma Cells | 4 | 2017 | 80 | 0.710 |
Why?
| | Haemophilus Vaccines | 4 | 2014 | 29 | 0.710 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2014 | 438 | 0.680 |
Why?
| | Immunity, Innate | 8 | 2016 | 844 | 0.680 |
Why?
| | Penicillin Resistance | 3 | 2017 | 9 | 0.680 |
Why?
| | Humans | 145 | 2026 | 146342 | 0.670 |
Why?
| | Adult | 64 | 2025 | 41087 | 0.630 |
Why?
| | Antibody Affinity | 5 | 2014 | 60 | 0.620 |
Why?
| | Cell Compartmentation | 1 | 2020 | 51 | 0.610 |
Why?
| | Immunoglobulin M | 13 | 2017 | 284 | 0.610 |
Why?
| | Pneumonia | 2 | 2023 | 635 | 0.590 |
Why?
| | Antibodies, Neutralizing | 3 | 2025 | 348 | 0.580 |
Why?
| | Female | 73 | 2025 | 79499 | 0.560 |
Why?
| | Immunoglobulin D | 2 | 2017 | 30 | 0.560 |
Why?
| | Immunity, Humoral | 2 | 2022 | 121 | 0.550 |
Why?
| | Breast Feeding | 4 | 2017 | 447 | 0.530 |
Why?
| | Uganda | 11 | 2025 | 91 | 0.530 |
Why?
| | HIV Antibodies | 6 | 2014 | 61 | 0.520 |
Why?
| | Anti-Retroviral Agents | 3 | 2014 | 250 | 0.520 |
Why?
| | Case-Control Studies | 13 | 2024 | 3647 | 0.510 |
Why?
| | Serogroup | 1 | 2017 | 46 | 0.500 |
Why?
| | Nasal Polyps | 1 | 2017 | 59 | 0.500 |
Why?
| | Male | 62 | 2025 | 73396 | 0.490 |
Why?
| | Middle Aged | 39 | 2025 | 36619 | 0.480 |
Why?
| | Down Syndrome | 1 | 2023 | 529 | 0.470 |
Why?
| | Neurosurgical Procedures | 1 | 2018 | 209 | 0.470 |
Why?
| | Sinusitis | 2 | 2017 | 221 | 0.460 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2016 | 141 | 0.460 |
Why?
| | Antibodies, Monoclonal | 6 | 2020 | 1512 | 0.460 |
Why?
| | Rhinitis | 1 | 2017 | 159 | 0.460 |
Why?
| | Disease | 1 | 2016 | 97 | 0.460 |
Why?
| | Dendritic Cells | 2 | 2016 | 509 | 0.460 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2017 | 1150 | 0.450 |
Why?
| | Infant, Newborn | 14 | 2023 | 6460 | 0.450 |
Why?
| | Haemophilus influenzae type b | 1 | 2014 | 12 | 0.430 |
Why?
| | Metagenome | 2 | 2012 | 127 | 0.410 |
Why?
| | Immunoglobulins | 5 | 2007 | 162 | 0.410 |
Why?
| | Giardia | 7 | 1990 | 8 | 0.410 |
Why?
| | Anti-HIV Agents | 6 | 2016 | 914 | 0.410 |
Why?
| | Giardiasis | 7 | 1990 | 20 | 0.410 |
Why?
| | Intestines | 3 | 2017 | 351 | 0.410 |
Why?
| | T-Lymphocytes | 6 | 2018 | 2012 | 0.410 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 263 | 0.400 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 3 | 0.400 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.400 |
Why?
| | Immunoglobulin A, Secretory | 5 | 2011 | 8 | 0.400 |
Why?
| | Bacterial Adhesion | 4 | 2019 | 109 | 0.400 |
Why?
| | Antibody Specificity | 7 | 2013 | 181 | 0.390 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 21 | 0.390 |
Why?
| | Burns | 1 | 2018 | 365 | 0.380 |
Why?
| | Antibody Formation | 5 | 2016 | 290 | 0.380 |
Why?
| | Genitalia, Female | 2 | 2012 | 43 | 0.380 |
Why?
| | Immunocompromised Host | 2 | 2009 | 201 | 0.370 |
Why?
| | Bacterial Proteins | 11 | 2019 | 980 | 0.370 |
Why?
| | Cytokines | 7 | 2025 | 2081 | 0.360 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2024 | 507 | 0.360 |
Why?
| | Cytotoxins | 4 | 1996 | 15 | 0.350 |
Why?
| | HIV Seropositivity | 5 | 2002 | 118 | 0.330 |
Why?
| | Pneumonia, Bacterial | 3 | 2004 | 114 | 0.320 |
Why?
| | Bacteremia | 3 | 1999 | 218 | 0.320 |
Why?
| | RNA, Viral | 7 | 2025 | 693 | 0.320 |
Why?
| | Mouth Mucosa | 4 | 2011 | 84 | 0.320 |
Why?
| | Infant | 17 | 2024 | 10114 | 0.310 |
Why?
| | Antibodies, Fungal | 1 | 2010 | 8 | 0.310 |
Why?
| | Vagina | 1 | 2012 | 202 | 0.300 |
Why?
| | Antiviral Agents | 3 | 2009 | 779 | 0.290 |
Why?
| | Viral Load | 6 | 2020 | 526 | 0.290 |
Why?
| | Amphotericin B | 4 | 2014 | 36 | 0.290 |
Why?
| | Influenza, Human | 3 | 2009 | 640 | 0.280 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1468 | 0.280 |
Why?
| | Aging | 6 | 2010 | 1996 | 0.280 |
Why?
| | Mycoses | 4 | 2014 | 87 | 0.270 |
Why?
| | Influenza Vaccines | 3 | 2009 | 544 | 0.270 |
Why?
| | Young Adult | 11 | 2025 | 14330 | 0.270 |
Why?
| | Transcription Factors | 1 | 2016 | 1730 | 0.270 |
Why?
| | Immunization, Passive | 2 | 2025 | 90 | 0.260 |
Why?
| | Immunity, Mucosal | 4 | 2011 | 97 | 0.260 |
Why?
| | Lipoproteins, IDL | 1 | 2007 | 1 | 0.260 |
Why?
| | Double-Blind Method | 4 | 2025 | 2070 | 0.250 |
Why?
| | Aged | 25 | 2025 | 26432 | 0.250 |
Why?
| | Lipoproteins, LDL | 1 | 2007 | 119 | 0.240 |
Why?
| | Hospitalization | 6 | 2025 | 2475 | 0.240 |
Why?
| | Prospective Studies | 12 | 2018 | 8123 | 0.240 |
Why?
| | Prevotella | 1 | 2026 | 27 | 0.240 |
Why?
| | Bacteria | 1 | 2012 | 766 | 0.240 |
Why?
| | Gene Expression | 3 | 2017 | 1463 | 0.230 |
Why?
| | Antibodies, Protozoan | 4 | 1990 | 41 | 0.230 |
Why?
| | Immunologic Memory | 4 | 2017 | 369 | 0.230 |
Why?
| | Bacterial Toxins | 3 | 1995 | 110 | 0.220 |
Why?
| | Immunoglobulin Heavy Chains | 3 | 2013 | 83 | 0.220 |
Why?
| | Myeloid Cells | 1 | 2026 | 149 | 0.220 |
Why?
| | Nose | 3 | 2015 | 67 | 0.220 |
Why?
| | Cryptosporidiosis | 3 | 1990 | 22 | 0.220 |
Why?
| | Veterans | 3 | 2025 | 1650 | 0.210 |
Why?
| | Mutation | 4 | 2014 | 4093 | 0.210 |
Why?
| | Animals | 27 | 2026 | 38107 | 0.210 |
Why?
| | Oropharynx | 1 | 2024 | 46 | 0.210 |
Why?
| | Flagellin | 1 | 2024 | 20 | 0.210 |
Why?
| | Proteins | 3 | 2001 | 1022 | 0.210 |
Why?
| | Adolescent | 16 | 2024 | 22557 | 0.210 |
Why?
| | Virus Replication | 5 | 2008 | 526 | 0.210 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2004 | 43 | 0.210 |
Why?
| | Enterotoxins | 2 | 1995 | 89 | 0.200 |
Why?
| | Child, Preschool | 12 | 2024 | 11913 | 0.200 |
Why?
| | Treatment Outcome | 7 | 2025 | 11821 | 0.200 |
Why?
| | Smallpox | 1 | 2003 | 10 | 0.200 |
Why?
| | HIV Seronegativity | 4 | 1995 | 28 | 0.200 |
Why?
| | Diphtheria Toxoid | 3 | 1999 | 13 | 0.200 |
Why?
| | Leukocyte Count | 3 | 2014 | 321 | 0.200 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 403 | 0.200 |
Why?
| | Chemokines | 2 | 2023 | 217 | 0.190 |
Why?
| | Genes, Immunoglobulin | 2 | 2000 | 29 | 0.190 |
Why?
| | Risk Factors | 9 | 2023 | 10921 | 0.190 |
Why?
| | Incidence | 2 | 2023 | 2936 | 0.190 |
Why?
| | Interleukin-15 | 1 | 2023 | 96 | 0.190 |
Why?
| | Leukocytes | 1 | 2025 | 301 | 0.190 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 88 | 0.190 |
Why?
| | Bacterial Infections | 4 | 2016 | 247 | 0.180 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 19 | 0.180 |
Why?
| | Interleukins | 2 | 2023 | 248 | 0.180 |
Why?
| | Disease Transmission, Infectious | 2 | 2004 | 69 | 0.180 |
Why?
| | Community-Acquired Infections | 3 | 1999 | 179 | 0.170 |
Why?
| | Molecular Sequence Data | 4 | 2013 | 2838 | 0.170 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 12 | 0.170 |
Why?
| | Enoxaparin | 1 | 2022 | 68 | 0.170 |
Why?
| | Interleukin-10 | 2 | 2021 | 310 | 0.170 |
Why?
| | RNA, Bacterial | 2 | 2012 | 183 | 0.170 |
Why?
| | Vaginal Discharge | 1 | 2001 | 2 | 0.170 |
Why?
| | Complement System Proteins | 2 | 2007 | 326 | 0.160 |
Why?
| | Infant, Newborn, Diseases | 1 | 2002 | 113 | 0.160 |
Why?
| | CD4 Lymphocyte Count | 8 | 2010 | 280 | 0.160 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 42 | 0.160 |
Why?
| | Gastric Mucosa | 1 | 2001 | 54 | 0.160 |
Why?
| | Cryptosporidium | 3 | 1990 | 15 | 0.160 |
Why?
| | Crohn Disease | 1 | 2024 | 250 | 0.160 |
Why?
| | Antigens, Protozoan | 3 | 1989 | 32 | 0.160 |
Why?
| | Biomarkers | 5 | 2021 | 4340 | 0.160 |
Why?
| | Protease Inhibitors | 1 | 2020 | 103 | 0.160 |
Why?
| | Virus Shedding | 2 | 2011 | 54 | 0.150 |
Why?
| | Cells, Cultured | 7 | 2015 | 4118 | 0.150 |
Why?
| | Salivary Glands | 2 | 1997 | 36 | 0.150 |
Why?
| | Cohort Studies | 8 | 2015 | 6077 | 0.150 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 203 | 0.150 |
Why?
| | Phagocytosis | 3 | 2026 | 298 | 0.150 |
Why?
| | B-Lymphocyte Subsets | 1 | 2000 | 78 | 0.150 |
Why?
| | Pregnancy | 8 | 2015 | 7230 | 0.150 |
Why?
| | Feces | 4 | 1990 | 496 | 0.150 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 7 | 2010 | 846 | 0.150 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 79 | 0.140 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2010 | 278 | 0.140 |
Why?
| | Phagocytes | 1 | 1999 | 79 | 0.140 |
Why?
| | Influenza B virus | 2 | 2009 | 47 | 0.140 |
Why?
| | Nitric Oxide | 2 | 2008 | 883 | 0.140 |
Why?
| | Cross Infection | 2 | 1999 | 258 | 0.140 |
Why?
| | Lung | 4 | 2026 | 4122 | 0.140 |
Why?
| | Coinfection | 1 | 2020 | 143 | 0.140 |
Why?
| | Africa | 2 | 2017 | 119 | 0.140 |
Why?
| | Nuclear Family | 1 | 1998 | 51 | 0.130 |
Why?
| | Klebsiella Infections | 1 | 1998 | 26 | 0.130 |
Why?
| | Influenza A virus | 2 | 2009 | 120 | 0.130 |
Why?
| | Klebsiella pneumoniae | 1 | 1998 | 48 | 0.130 |
Why?
| | Cholera | 1 | 1997 | 9 | 0.130 |
Why?
| | Syndecan-1 | 1 | 2017 | 42 | 0.130 |
Why?
| | Endocarditis, Bacterial | 1 | 1998 | 46 | 0.130 |
Why?
| | Disease Susceptibility | 2 | 2017 | 339 | 0.130 |
Why?
| | Candidiasis | 2 | 1995 | 64 | 0.130 |
Why?
| | Amino Acid Motifs | 2 | 2017 | 218 | 0.130 |
Why?
| | Pharynx | 2 | 1998 | 60 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2018 | 324 | 0.130 |
Why?
| | Lymphopoiesis | 1 | 2017 | 27 | 0.120 |
Why?
| | Nitric Oxide Synthase | 1 | 1997 | 233 | 0.120 |
Why?
| | Mucus | 1 | 2017 | 75 | 0.120 |
Why?
| | Paranasal Sinuses | 1 | 2017 | 77 | 0.120 |
Why?
| | Aged, 80 and over | 8 | 2008 | 8391 | 0.120 |
Why?
| | Monocytes | 2 | 2000 | 538 | 0.120 |
Why?
| | Mice | 8 | 2026 | 18297 | 0.120 |
Why?
| | Neutralization Tests | 2 | 2013 | 74 | 0.120 |
Why?
| | Receptors, CCR5 | 1 | 2017 | 59 | 0.120 |
Why?
| | Antigens, Bacterial | 3 | 2007 | 125 | 0.120 |
Why?
| | Immunization | 5 | 2005 | 376 | 0.120 |
Why?
| | United States | 7 | 2024 | 16136 | 0.120 |
Why?
| | Intestine, Small | 1 | 1997 | 160 | 0.120 |
Why?
| | Cell Communication | 1 | 2018 | 327 | 0.120 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 21 | 0.120 |
Why?
| | Nasal Mucosa | 2 | 2014 | 112 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2016 | 4580 | 0.110 |
Why?
| | Plasma | 2 | 2012 | 222 | 0.110 |
Why?
| | Gastrointestinal Diseases | 3 | 2001 | 220 | 0.110 |
Why?
| | Protective Factors | 1 | 2015 | 97 | 0.110 |
Why?
| | Virulence Factors | 1 | 2017 | 175 | 0.110 |
Why?
| | Measles | 1 | 1995 | 48 | 0.110 |
Why?
| | Pregnancy Trimester, First | 1 | 2015 | 140 | 0.110 |
Why?
| | Time Factors | 11 | 2012 | 7109 | 0.110 |
Why?
| | Blood Cells | 1 | 2014 | 38 | 0.110 |
Why?
| | DNA, Bacterial | 3 | 2012 | 319 | 0.110 |
Why?
| | Clostridium | 1 | 1994 | 19 | 0.110 |
Why?
| | Prevalence | 3 | 2017 | 2861 | 0.110 |
Why?
| | Intestinal Diseases, Parasitic | 3 | 1989 | 12 | 0.110 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 245 | 0.110 |
Why?
| | Critical Illness | 2 | 2018 | 908 | 0.110 |
Why?
| | Type C Phospholipases | 1 | 1994 | 69 | 0.100 |
Why?
| | Complementarity Determining Regions | 1 | 2014 | 54 | 0.100 |
Why?
| | Mutation Rate | 1 | 2014 | 37 | 0.100 |
Why?
| | Cell Line | 4 | 2007 | 2814 | 0.100 |
Why?
| | Blood Proteins | 1 | 2015 | 239 | 0.100 |
Why?
| | Carrier State | 2 | 2015 | 80 | 0.100 |
Why?
| | Immunoglobulin Class Switching | 1 | 2013 | 21 | 0.100 |
Why?
| | B-Cell Maturation Antigen | 1 | 2013 | 17 | 0.100 |
Why?
| | Clostridium Infections | 1 | 1994 | 75 | 0.100 |
Why?
| | Immunization, Secondary | 2 | 2010 | 94 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 2 | 2024 | 769 | 0.100 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 171 | 0.100 |
Why?
| | Chronic Disease | 2 | 2017 | 1827 | 0.100 |
Why?
| | Blood Bactericidal Activity | 3 | 1999 | 38 | 0.100 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 59 | 0.100 |
Why?
| | Child | 8 | 2024 | 22693 | 0.090 |
Why?
| | Sequence Alignment | 1 | 2013 | 360 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2021 | 1224 | 0.090 |
Why?
| | Cell Count | 1 | 2013 | 315 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 297 | 0.090 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1992 | 29 | 0.090 |
Why?
| | Cytoplasm | 1 | 2013 | 253 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2092 | 0.090 |
Why?
| | Burkina Faso | 1 | 2012 | 7 | 0.090 |
Why?
| | Nevirapine | 1 | 2012 | 17 | 0.090 |
Why?
| | Predictive Value of Tests | 4 | 2008 | 2113 | 0.090 |
Why?
| | Agglutination | 2 | 2014 | 5 | 0.090 |
Why?
| | Cell Movement | 1 | 2017 | 951 | 0.090 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 253 | 0.090 |
Why?
| | Genes, Bacterial | 1 | 2012 | 151 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2023 | 17438 | 0.090 |
Why?
| | HIV Envelope Protein gp120 | 2 | 2013 | 55 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 1993 | 337 | 0.090 |
Why?
| | Mammary Glands, Human | 1 | 2012 | 71 | 0.090 |
Why?
| | Structure-Activity Relationship | 2 | 2007 | 563 | 0.090 |
Why?
| | Saliva | 4 | 2011 | 256 | 0.090 |
Why?
| | Premature Birth | 1 | 2015 | 390 | 0.080 |
Why?
| | Morphogenesis | 1 | 2012 | 163 | 0.080 |
Why?
| | Adenovirus Infections, Human | 1 | 1991 | 15 | 0.080 |
Why?
| | DNA Fingerprinting | 1 | 1991 | 28 | 0.080 |
Why?
| | Enterocolitis | 1 | 1991 | 18 | 0.080 |
Why?
| | Pseudomonas | 1 | 1991 | 30 | 0.080 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 397 | 0.080 |
Why?
| | Proteinase Inhibitory Proteins, Secretory | 3 | 2001 | 3 | 0.080 |
Why?
| | Lactation | 1 | 2012 | 193 | 0.080 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 3 | 2001 | 5 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 1993 | 385 | 0.080 |
Why?
| | Inflammation | 2 | 2021 | 2919 | 0.080 |
Why?
| | Multigene Family | 2 | 2002 | 210 | 0.080 |
Why?
| | Virulence | 4 | 1997 | 288 | 0.080 |
Why?
| | Mothers | 1 | 2017 | 772 | 0.080 |
Why?
| | Mucous Membrane | 1 | 2011 | 130 | 0.080 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 459 | 0.080 |
Why?
| | Survival Analysis | 4 | 2025 | 1378 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2013 | 2791 | 0.080 |
Why?
| | Virus Diseases | 3 | 1992 | 219 | 0.080 |
Why?
| | Gene Frequency | 2 | 2002 | 496 | 0.080 |
Why?
| | Viruses | 1 | 2012 | 165 | 0.080 |
Why?
| | Tetanus Toxoid | 2 | 2005 | 34 | 0.080 |
Why?
| | Child Day Care Centers | 1 | 1990 | 36 | 0.080 |
Why?
| | Research | 2 | 2010 | 421 | 0.070 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 104 | 0.070 |
Why?
| | Epithelial Cells | 3 | 2008 | 1119 | 0.070 |
Why?
| | Macrophages | 3 | 2026 | 1532 | 0.070 |
Why?
| | Recombinant Proteins | 2 | 2007 | 1361 | 0.070 |
Why?
| | Immunity, Herd | 1 | 2008 | 7 | 0.070 |
Why?
| | Pseudomonas Infections | 1 | 1991 | 229 | 0.070 |
Why?
| | Exercise | 1 | 2021 | 2213 | 0.070 |
Why?
| | Geriatrics | 1 | 2010 | 96 | 0.070 |
Why?
| | Infant, Premature | 1 | 2013 | 622 | 0.070 |
Why?
| | Base Sequence | 1 | 2012 | 2123 | 0.070 |
Why?
| | Models, Molecular | 3 | 2020 | 1574 | 0.070 |
Why?
| | Anti-Infective Agents | 2 | 2004 | 234 | 0.070 |
Why?
| | Duodenum | 2 | 2002 | 76 | 0.070 |
Why?
| | Suicide | 1 | 2015 | 647 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2008 | 429 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3206 | 0.070 |
Why?
| | Phylogeny | 1 | 2012 | 924 | 0.070 |
Why?
| | Virus Integration | 1 | 2008 | 69 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 77 | 0.070 |
Why?
| | Opportunistic Infections | 4 | 1992 | 47 | 0.070 |
Why?
| | Cytomegalovirus Infections | 1 | 1990 | 206 | 0.070 |
Why?
| | Botswana | 1 | 2007 | 11 | 0.070 |
Why?
| | Coccidia | 1 | 1987 | 2 | 0.060 |
Why?
| | Neutrophils | 2 | 2026 | 1133 | 0.060 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 231 | 0.060 |
Why?
| | Campylobacter jejuni | 1 | 2007 | 16 | 0.060 |
Why?
| | Immunoassay | 1 | 2008 | 108 | 0.060 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2008 | 127 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1064 | 0.060 |
Why?
| | Salivary Proteins and Peptides | 2 | 1997 | 14 | 0.060 |
Why?
| | Child Development | 1 | 2012 | 481 | 0.060 |
Why?
| | Keratinocytes | 1 | 2008 | 190 | 0.060 |
Why?
| | Helicobacter pylori | 1 | 2007 | 44 | 0.060 |
Why?
| | Lipids | 2 | 2007 | 714 | 0.060 |
Why?
| | Urinalysis | 1 | 2007 | 82 | 0.060 |
Why?
| | Interleukin-6 | 3 | 2021 | 784 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2008 | 186 | 0.060 |
Why?
| | Serine Proteinase Inhibitors | 2 | 1997 | 48 | 0.060 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 186 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2007 | 67 | 0.060 |
Why?
| | Prednisone | 1 | 1987 | 229 | 0.060 |
Why?
| | Zidovudine | 2 | 2004 | 75 | 0.060 |
Why?
| | Methotrexate | 1 | 1987 | 234 | 0.060 |
Why?
| | HIV | 1 | 2007 | 249 | 0.060 |
Why?
| | Sepsis | 1 | 1993 | 669 | 0.060 |
Why?
| | Neuralgia | 1 | 1987 | 141 | 0.060 |
Why?
| | Ileum | 2 | 1997 | 112 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 1992 | 952 | 0.060 |
Why?
| | HTLV-II Infections | 1 | 2005 | 3 | 0.060 |
Why?
| | Rabbits | 2 | 1997 | 651 | 0.060 |
Why?
| | Colon | 2 | 2002 | 304 | 0.060 |
Why?
| | Fluconazole | 1 | 2025 | 24 | 0.050 |
Why?
| | Secretory Component | 1 | 2004 | 1 | 0.050 |
Why?
| | Neuraminidase | 1 | 2004 | 27 | 0.050 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2004 | 16 | 0.050 |
Why?
| | Immunodominant Epitopes | 1 | 2024 | 27 | 0.050 |
Why?
| | Lactoferrin | 1 | 2004 | 37 | 0.050 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2024 | 20 | 0.050 |
Why?
| | Sweden | 1 | 2024 | 114 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 6034 | 0.050 |
Why?
| | Herpes Zoster | 1 | 1987 | 318 | 0.050 |
Why?
| | Smallpox Vaccine | 1 | 2003 | 23 | 0.050 |
Why?
| | Kinetics | 2 | 1997 | 1553 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 36 | 0.050 |
Why?
| | Signal Transduction | 1 | 2016 | 5246 | 0.050 |
Why?
| | Acute Disease | 2 | 1995 | 1038 | 0.050 |
Why?
| | Colony Count, Microbial | 2 | 2014 | 90 | 0.050 |
Why?
| | Therapeutic Irrigation | 1 | 2002 | 69 | 0.050 |
Why?
| | Hemolysis | 2 | 1994 | 242 | 0.040 |
Why?
| | Complement Activation | 2 | 1996 | 412 | 0.040 |
Why?
| | Molecular Weight | 2 | 1995 | 295 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 79 | 0.040 |
Why?
| | Protozoan Infections | 3 | 1992 | 11 | 0.040 |
Why?
| | Bacterial Typing Techniques | 2 | 2010 | 40 | 0.040 |
Why?
| | Dysbiosis | 1 | 2022 | 184 | 0.040 |
Why?
| | Vitamin A | 1 | 2001 | 60 | 0.040 |
Why?
| | Biocatalysis | 1 | 2020 | 68 | 0.040 |
Why?
| | Thailand | 2 | 1990 | 20 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2001 | 117 | 0.040 |
Why?
| | Interphase | 1 | 2000 | 38 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 928 | 0.040 |
Why?
| | State Medicine | 1 | 1980 | 23 | 0.040 |
Why?
| | Blood | 2 | 2004 | 107 | 0.040 |
Why?
| | Respiratory Mucosa | 1 | 2003 | 323 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2000 | 167 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 771 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 172 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1486 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 26 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2020 | 235 | 0.040 |
Why?
| | Cryoelectron Microscopy | 1 | 2020 | 182 | 0.040 |
Why?
| | Gene Products, nef | 1 | 1999 | 12 | 0.040 |
Why?
| | Drug Interactions | 1 | 2001 | 405 | 0.040 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1999 | 34 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2022 | 750 | 0.040 |
Why?
| | Metabolic Diseases | 2 | 2012 | 114 | 0.040 |
Why?
| | Chemotaxis | 1 | 1999 | 121 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 1998 | 58 | 0.040 |
Why?
| | DNA Restriction Enzymes | 1 | 1998 | 46 | 0.030 |
Why?
| | Colorado | 3 | 1997 | 4595 | 0.030 |
Why?
| | Public Health | 1 | 2003 | 574 | 0.030 |
Why?
| | Exudates and Transudates | 1 | 1998 | 12 | 0.030 |
Why?
| | Quality Control | 1 | 1998 | 163 | 0.030 |
Why?
| | Molsidomine | 1 | 1997 | 5 | 0.030 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 1997 | 6 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 3 | 2009 | 585 | 0.030 |
Why?
| | Cholera Toxin | 1 | 1997 | 27 | 0.030 |
Why?
| | Vibrio cholerae | 1 | 1997 | 14 | 0.030 |
Why?
| | Peru | 1 | 1997 | 61 | 0.030 |
Why?
| | Nitrites | 1 | 1997 | 85 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 1998 | 66 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 678 | 0.030 |
Why?
| | Jejunum | 1 | 1997 | 36 | 0.030 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 348 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 1997 | 152 | 0.030 |
Why?
| | Cause of Death | 2 | 2014 | 456 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 1997 | 367 | 0.030 |
Why?
| | Catalysis | 1 | 2017 | 304 | 0.030 |
Why?
| | Reference Values | 1 | 1997 | 796 | 0.030 |
Why?
| | Cell Separation | 1 | 1997 | 300 | 0.030 |
Why?
| | Antibiosis | 1 | 2015 | 10 | 0.030 |
Why?
| | Streptococcus mitis | 1 | 2015 | 10 | 0.030 |
Why?
| | Lactobacillus | 1 | 2015 | 28 | 0.030 |
Why?
| | Hypokalemia | 1 | 1995 | 23 | 0.030 |
Why?
| | Antibody-Producing Cells | 1 | 1995 | 30 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 1995 | 50 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 1999 | 931 | 0.030 |
Why?
| | Age Factors | 2 | 1995 | 3347 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 384 | 0.030 |
Why?
| | Catalase | 1 | 2015 | 133 | 0.030 |
Why?
| | Drug Tolerance | 1 | 1995 | 100 | 0.030 |
Why?
| | Kenya | 1 | 1995 | 129 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 38 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1995 | 55 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 315 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1995 | 224 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2010 | 1503 | 0.030 |
Why?
| | Potassium | 1 | 1995 | 151 | 0.030 |
Why?
| | Complement C5 | 1 | 1995 | 33 | 0.030 |
Why?
| | Gas Gangrene | 1 | 1994 | 2 | 0.030 |
Why?
| | Immunocompetence | 1 | 1994 | 46 | 0.030 |
Why?
| | Cerebrospinal Fluid Otorrhea | 1 | 2014 | 4 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1993 | 1041 | 0.030 |
Why?
| | Transforming Growth Factor beta | 2 | 1994 | 467 | 0.030 |
Why?
| | Syndrome | 1 | 1995 | 380 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2014 | 47 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2244 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 823 | 0.030 |
Why?
| | Immune Evasion | 1 | 2014 | 64 | 0.020 |
Why?
| | Creatinine | 1 | 1995 | 511 | 0.020 |
Why?
| | Peptide Hydrolases | 1 | 2014 | 105 | 0.020 |
Why?
| | South Africa | 1 | 2014 | 262 | 0.020 |
Why?
| | Pandemics | 1 | 2022 | 1707 | 0.020 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1997 | 1712 | 0.020 |
Why?
| | Pilot Projects | 1 | 1998 | 1888 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 53 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1031 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2000 | 1982 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 790 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 382 | 0.020 |
Why?
| | Measles Vaccine | 1 | 1991 | 21 | 0.020 |
Why?
| | Milk | 1 | 2012 | 117 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 543 | 0.020 |
Why?
| | Vaccines | 1 | 1996 | 389 | 0.020 |
Why?
| | Mammary Glands, Animal | 1 | 2012 | 124 | 0.020 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 1991 | 19 | 0.020 |
Why?
| | Gastroenteritis | 2 | 1989 | 63 | 0.020 |
Why?
| | Mice, Knockout | 1 | 1998 | 3125 | 0.020 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1991 | 26 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 26 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2010 | 2921 | 0.020 |
Why?
| | Rats | 2 | 2004 | 5586 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1991 | 161 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2010 | 14 | 0.020 |
Why?
| | Diarrhea, Infantile | 1 | 1990 | 4 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2599 | 0.020 |
Why?
| | Institutionalization | 1 | 1990 | 12 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 117 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 90 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2126 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 23 | 0.020 |
Why?
| | Cell Survival | 1 | 1993 | 1105 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 83 | 0.020 |
Why?
| | Interleukin-17 | 1 | 2010 | 121 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 207 | 0.020 |
Why?
| | Sampling Studies | 1 | 1990 | 97 | 0.020 |
Why?
| | Health | 1 | 2010 | 81 | 0.020 |
Why?
| | Nasal Cavity | 1 | 2010 | 60 | 0.020 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2009 | 39 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 158 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 80 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2010 | 161 | 0.020 |
Why?
| | Cattle | 1 | 1992 | 940 | 0.020 |
Why?
| | Sex Factors | 1 | 1995 | 2107 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2012 | 888 | 0.020 |
Why?
| | Counterimmunoelectrophoresis | 1 | 1989 | 3 | 0.020 |
Why?
| | Cross Reactions | 1 | 1989 | 130 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5899 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 576 | 0.020 |
Why?
| | Homosexuality | 1 | 1988 | 18 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 779 | 0.020 |
Why?
| | False Positive Reactions | 1 | 1989 | 124 | 0.020 |
Why?
| | Immunization Schedule | 1 | 2010 | 187 | 0.020 |
Why?
| | Proteomics | 1 | 2015 | 1203 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 614 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2008 | 137 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 31 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2008 | 55 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1998 | 5439 | 0.020 |
Why?
| | Forecasting | 1 | 2010 | 388 | 0.020 |
Why?
| | Fluticasone | 1 | 2008 | 53 | 0.020 |
Why?
| | Nutritional Status | 1 | 1990 | 346 | 0.020 |
Why?
| | Albuterol | 1 | 2008 | 76 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2008 | 245 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 287 | 0.020 |
Why?
| | Kidney | 1 | 1995 | 1498 | 0.020 |
Why?
| | Immunity | 1 | 2008 | 141 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 1734 | 0.020 |
Why?
| | Specimen Handling | 1 | 1989 | 178 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2134 | 0.020 |
Why?
| | Age Distribution | 1 | 2008 | 399 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2010 | 508 | 0.020 |
Why?
| | Biopsy | 1 | 1991 | 1075 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 314 | 0.020 |
Why?
| | Spirometry | 1 | 2008 | 234 | 0.020 |
Why?
| | Military Personnel | 1 | 1995 | 726 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 1133 | 0.020 |
Why?
| | Health Resources | 1 | 2008 | 131 | 0.020 |
Why?
| | Cough | 1 | 2008 | 123 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2008 | 268 | 0.020 |
Why?
| | Virus Activation | 1 | 1987 | 97 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 385 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2008 | 451 | 0.020 |
Why?
| | Disease Progression | 3 | 1999 | 2867 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 567 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 300 | 0.020 |
Why?
| | Hemophilia A | 1 | 1989 | 150 | 0.020 |
Why?
| | Fever | 1 | 2008 | 322 | 0.010 |
Why?
| | Antitubercular Agents | 1 | 2008 | 212 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1990 | 1543 | 0.010 |
Why?
| | ROC Curve | 1 | 2008 | 617 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1989 | 422 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 252 | 0.010 |
Why?
| | Inpatients | 1 | 2010 | 540 | 0.010 |
Why?
| | Chemokine CCL5 | 1 | 2005 | 40 | 0.010 |
Why?
| | Biomedical Research | 1 | 2012 | 729 | 0.010 |
Why?
| | Liver Diseases | 1 | 2008 | 304 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 2005 | 73 | 0.010 |
Why?
| | Immune Tolerance | 1 | 1987 | 386 | 0.010 |
Why?
| | Poverty | 1 | 2008 | 530 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2008 | 428 | 0.010 |
Why?
| | Perinatal Care | 1 | 2004 | 61 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1763 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2004 | 127 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 6073 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 642 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 752 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 3017 | 0.010 |
Why?
| | Cuba | 1 | 1980 | 15 | 0.010 |
Why?
| | Occupational Health Services | 1 | 1980 | 36 | 0.010 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.010 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 19 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 31 | 0.010 |
Why?
| | Macaca | 1 | 1999 | 66 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1999 | 112 | 0.010 |
Why?
| | Encephalitis, Viral | 1 | 1999 | 45 | 0.010 |
Why?
| | Simian Immunodeficiency Virus | 1 | 1999 | 94 | 0.010 |
Why?
| | Adenoviridae | 1 | 1999 | 197 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1980 | 100 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2000 | 778 | 0.010 |
Why?
| | Deoxycholic Acid | 1 | 1998 | 14 | 0.010 |
Why?
| | Quinine | 1 | 1998 | 20 | 0.010 |
Why?
| | Centrifugation | 1 | 1997 | 29 | 0.010 |
Why?
| | Didanosine | 1 | 1996 | 13 | 0.010 |
Why?
| | Proviruses | 1 | 1996 | 16 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 1996 | 64 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2000 | 1331 | 0.010 |
Why?
| | DNA, Viral | 1 | 1996 | 354 | 0.010 |
Why?
| | Mental Health Services | 1 | 1980 | 450 | 0.010 |
Why?
| | Nucleic Acids | 1 | 1995 | 78 | 0.010 |
Why?
| | Mitosis | 1 | 1995 | 195 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1163 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1998 | 0.010 |
Why?
| | Cell Nucleus | 1 | 1995 | 584 | 0.010 |
Why?
| | Vermont | 1 | 1989 | 13 | 0.000 |
Why?
| | Water Supply | 1 | 1989 | 90 | 0.000 |
Why?
| | Rural Population | 1 | 1989 | 677 | 0.000 |
Why?
|
|
Janoff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|